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Continuous growth of the end stage renal disease population
treated by dialysis, outpaces deceased donor kidneys
available, lengthens the waiting time for a deceased donor
transplant. As estimated by the United States Department
of Health & Human Services: ‘17 people die each day
waiting for transplants that can’t take place because of the
shortage of donated organs.’ Strategies to expand the donor
pool – public relations campaigns and Drivers’ license
designation – have been mainly unsuccessful. Although
illegal in most nations, and viewed as unethical by
professional medical organizations, the voluntary sale of
purchased donor kidneys now accounts for thousands
of black market transplants. The case for legalizing kidney
purchase hinges on the key premise that individuals are
entitled to control of their body parts even to the point of
inducing risk of life. One approach to expanding the pool
of kidney donors is to legalize payment of a fair market price
of about $40 000 to donors. Establishing a federal agency
to manage marketing and purchase of donor kidneys in
collaboration with the United Network for Organ Sharing
might be financially self-sustaining as reduction in costs of
dialysis balances the expense of payment to donors.
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In early September, 2005, 65 000 candidates were listed in the
United States by the Organ Procurement and Transplant
Network as waiting for a deceased donor kidney (http://
www.optn.org/latestData/rptData.asp).1 At least 3000, of
those on the wait list who will die each year might have
survived had a suitable donor kidney been available.2 The
United States Department of Health and Human Services
advises: ‘Each day, about 74 people receive an organ
transplant. However, 17 people die each day waiting for
transplants that cannot take place because of the shortage of
donated organs.’
Intensive public relations efforts, celebrity endorsements,
National Kidney Foundation efforts and State Drivers License
advance permission have not increased the number of
deceased donor kidney transplants in the United States over
the past decade. As listed by the United Network for Organ
Sharing,3 while kidney transplants performed between 1988
(8873) and 2004 (16 004) increased by 80.3%, deceased organ
transplants in the same interval increased only 32.5% from
7061 to 9357).
To address this shortage of donor kidneys, acceptance of
what previously have been termed ‘marginal’ kidneys termed
‘expanded criteria donors’ from geriatric, hypertensive, and
even proteinuric donors has increased progressively.4 Pur-
chasing kidneys from compensated donors, a highly con-
troversial and evocative issue, has gradually evolved from an
unmentionable practice performed occultly in developing
(poor) countries to be openly debated by the American
Society of Nephrology and the American Transplantation
Society.
Selling a human organ in the United States is proscribed.
The National Organ Transplant Act states: ‘It shall be unlawful
for any person to knowingly acquire, receive, or otherwise
transfer any human organ for valuable consideration for use
in human transplantation if the transfer affects interstate
commerce’5 Punishment includes fines up to $50 000 and/or
5 years in prison, but has not been meted out. A year after
enactment of National Organ Transplant Act, the Ethics
Committee of the Transplantation Society issued a supporting
Policy Statement: ‘No transplant surgeon/team shall be
involved directly or indirectly in the buying or selling of
organs/tissues or in any transplant activity aimed at
commercial gain to himself/herself or an associated hospital
or institute.’6 Within 5 years, several countries and the World
Health Organization issued similar bans.7
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Medical associations globally decry the sale of human
organs, transactions deemed ‘morally and ethically irrespon-
sible,’ or ‘inhumane and unacceptable.’ Berkeley anthropol-
ogy professor Nancy Scheper-Hughes who has studied actual
conditions and consequences of kidney sales in Brazil and
other countries believes permitting legal solid organ sales
would permit ‘one relatively privileged population [to] claim
property rights over the bodies of the disadvantaged.’8
Near universal strong condemnations of selling organs
have been issued by voluntary health agencies and religious
authorities including Pope John Paul II who wrote that
buying and selling organs violates ‘the dignity of the human
person.’9 American transplantation associations repeatedly
endorsed the stance that paying donors for their organs was
not only illegal but unethical. Furthermore, the American
Society of Transplant Surgeons expounded the position that
solicitation for organ donation is inappropriate, even absent
the exchange of ‘valuable consideration’: The American
Society of Transplant Surgeons is opposed solicitation of
organs (deceased) or organ donors (live) by recipients or
their agents, whether through personal or commercial
websites, billboards, media outlets, or any advertising when
the intent of such solicitation is to redirect the donation to a
specific individual rather than according to the fair policies of
allocation (United Network for Organ Sharing policy on
organ allocation).10
What then might ease the shortage of kidney donors?
Congress has been urged to conduct a trial to assess the value
of compensating deceased donor families as well as to test
some form of payment to live kidney donors. Dr Francis L
Delmonico, Director of renal transplantation at Massachusetts
General Hospital, speaking on behalf of the National Kidney
Foundation, testified to congress: ‘Congressional endorsement
of a payment for organs y could propel other countries to
sanction an unethical and unjust standard of immense
proportions, one in which the wealthy readily obtain organs
from the poor, justified by the citation of congressional
sanction. In that reality, the poor person will remain poor but
lose health and maybe more than one organ in the process of
a government authorized abuse of the poor for the rich.’11
By contrast, some transplant surgeons advocate regulated
sale of kidneys to prevent death of as many as 100 000 people
annually. At the American Transplantation Congress, Arthur
Matas of the University of Minnesota transplant team, noting
that a wait time of over 5 years, induces death on the waiting
list of 7% annually, called for a regulated system of living
kidney sales.12 The Matas proposal includes careful donor
medical and psychosocial evaluations with a fixed tax-free
payment to the donor plus an option of short- or long-term
health and life insurance. Matas pointed out that surrogate
mothers are individuals who benefit others without losing
their dignity or becoming victims. Similarly, paid organ
donors are not victims who unable to determine what
happens to their body.
In early 2006, the lessons learned from the wild and
extensive racketeering spawned by America’s 1920s ‘Prohibi-
tion’ of alcoholic beverages are pertinent. Clearly, legislation,
per se, may not force human behavior compliance.13 Thus,
while the sale of human organs is against existing law, in
nearly every country, illegal kidney transplants are widely
available through devious and often unsavory vendors in
India, Turkey, China, Russia, and South Africa as described in
the New York Times.14 Organs Watch, a non-government
transplant monitoring organization, estimates that ‘ythou-
sands of illegal transplants occur every year bought by
patients from the Persian Gulf states, Japan, Italy, Israel, the
US and Canada supplied by ‘donor’ nations, including India,
Pakistan, Turkey, Peru, Mexico, Romania, and South
Africa.’15 The late Michael Friedlaender, a transplant
nephrologist at Hadassah University Hospital in Israel,
remarked: ‘What’s happening now is absurd. Airplanes are
leaving every week. I’ve seen 300 of my patients go abroad
and come back with new kidneysy it’s a free-for-all.’16
Friedlander characterized today’s kidney market as forcing
potential kidney purchasers to be ‘exposed to unscrupulous
treatment by uncontrolled free enterprise.’
Voices favoring kidney sales are becoming more evident.
For example, a surprisingly positive endorsement for
legalizing human organ sales was provided by Robert Berman
of the Orthodox Jewish Halachic (interpreted by orthodox
rabbis) Organ Donor Society writing in the Jerusalem Post of
9 August 2005: ‘The choice before us in not between buying
or not buying organs. This is happening regardless of the law.
The choice is whether transplant operations and the sale of
organs will be regulated or not.’17
Nobel Laureate (Economics), Gary S Becker and his co-
worker Julio J Elias established a ‘market price’ for a live
donor kidney as a commodity.18 Assuming that an American
earning a mean of $40 000 annually has a life valued at $3
million, faces a risk of death from nephrectomy of 1%, a
decrease of 5% in quality of life, and will lose $7000 of
income due to convalescence from surgery, they calculated a
kidney purchase price of $45 000. Using a more probable
death risk of one in 300 nephrectomies (the true reported risk
is three in 10 000);19 reduces the kidney price to $20 000. Our
current non-system promotes a kidney black market available
only to the wealthy who bear the total expense for what may
be inadequately screened, suboptimally matched organs
inserted by unregulated (inferior?) surgeons. Becker and
Elias’s proposal would end advantages of wealth in organ
acquisition since poorer individuals would obtain their
kidneys via Medicaid or Medicare.
Each of us may opt to engage in risky behaviors (e.g. sky
diving, volunteering for military service, working on oil rigs,
and smoking cigarettes). Lacking wealth does not preempt
making a rational decision. Prohibiting the poor from
donating organs leaves them still poor; consequently,
according to Matas, withholding the ability to be paid for
donation eliminates one path to improve a person’s financial
situation. Just what is so ethically wrong? How is it worse
than selling one’s sperm or egg cells, actions now legal and
widely advertised? Indeed, commercialization of semen and
Kidney International (2006) 69, 960–962 961
EA Friedman and AL Friedman: Payment for donor kidneys m i n i r e v i e w
ova is more morally questionable than organ sale because
those cells might create entirely new human beings.
In his ‘Advice to the Ethics Committee of the Transplanta-
tion Society,’ AS Daar, Director of the Program in Applied
Ethics and Biotechnology, University of Toronto, writes: ‘The
position of the Transplantation Society is that the buying and
selling of organs is wrong, that we must base transplantation
on altruism, that we must encourage legislation to ban
commerce, and that any member of the Transplantation
Society who participates in the buying and selling of organs
will be expelled from the society. Adopting this position on
its own has been totally useless in stopping the increase of the
buying and selling of organs.’20 Trong21 recently thoughtfully
reassessed the ethics of accepting living donor organs.
Introducing appropriate legalization to regulate and
manage kidney sales through a national regulatory body
would be a ‘natural’ extension of the present end stage renal
disease network collaborating with United Network for
Organ Sharing and the OPTN. Eliminating black market
brokers would divert funds to kidney sellers. Money saved by
decreasing the number of dialysis patients might fund
additional kidney transplants. Reservations that adoption
of a federal organ marketing scheme necessitates further
‘socialization’ of our health care system are reasonable.
Insertion of yet another federal agency to ‘supervise’
presently over regulated nephrologists and transplant sur-
geons is a less than attractive proposition. But, the mandate
underlying this essay is consideration of endorsement of a
strategy for resolution of a problem that has grown into a
serious conundrum. At the least, debating the controlled
initiation and study of potential regimens that may increase
donor kidney supply in the future in a scientifically and
ethically responsible manner, is better than doing nothing
more productive than complaining about the current
system’s failure.
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